Epigenetic modification in gliomas: role of the histone methyltransferase EZH2

Bibliography

• Hamza MA, Gilbert M. Targeted therapy in gliomas. Curr Oncol Rep 2014;16(4):379
   PubMed Web of Science ®Google Scholar
• Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006;1:97-117
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114(2):97-109
   PubMed Web of Science ®Google Scholar
• Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010;177(6):2708-14
   PubMed Web of Science ®Google Scholar
• Gupta K, Salunke P. Molecular markers of glioma: an update on recent progress and perspectives. J Cancer Res Clin Oncol 2012;138(12):1971-81
   PubMed Web of Science ®Google Scholar
• Gupta M, Djalilvand A, Brat DJ. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Am J Clin Pathol 2005;124(5):755-68
   PubMed Web of Science ®Google Scholar
• Perry A. Pathology of low-grade gliomas: an update of emerging concepts. Neuro Oncol 2003;5(3):168-78
   PubMedGoogle Scholar
• Benjamin R, Capparella J, Brown A. Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J 2003;9(2):82-90
   PubMed Web of Science ®Google Scholar
• Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005 – 2009. Neuro Oncol 2012;14(Suppl 5):v1-49
   PubMed Web of Science ®Google Scholar
• De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol 2012;30(20):2559-65
   PubMed Web of Science ®Google Scholar
• Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008;26(8):1338-45
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90
   PubMed Web of Science ®Google Scholar
• Weller M, Stupp R, Hegi M, et al. Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J 2012;18(1):40-4
   PubMedGoogle Scholar
• Hadjipanayis CG, Van Meir EG. Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med (Berl) 2009;87(4):363-74
   PubMed Web of Science ®Google Scholar
• Cheng L, Bao S, Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 2010;80(5):654-65
   PubMed Web of Science ®Google Scholar
• Vermeulen L, de Sousa e Melo F, Richel DJ, et al. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 2012;13(2):e83-9
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8(10):755-68
   PubMed Web of Science ®Google Scholar
• Natsume A, Ito M, Katsushima K, et al. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. Cancer Res 2013;73(14):4559-70
   PubMed Web of Science ®Google Scholar
• Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer 2006;6(6):425-36
   PubMed Web of Science ®Google Scholar
• Cardoso C, Mignon C, Hetet G, et al. The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Hum Genet 2000;8(3):174-80
   PubMedGoogle Scholar
• Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011;469(7330):343-9
   PubMed Web of Science ®Google Scholar
• Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;298(5595):1039-43
   PubMed Web of Science ®Google Scholar
• Kuzmichev A, Nishioka K, Erdjument-Bromage H, et al. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 2002;16(22):2893-905
   PubMed Web of Science ®Google Scholar
• Muller J, Hart CM, Francis N J, et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 2002;111(2):197-208
   PubMed Web of Science ®Google Scholar
• Lachner M, O’Carroll D, Rea S, et al. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 2001;410(6824):116-20
   PubMed Web of Science ®Google Scholar
• Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010;7(3):299-313
   PubMed Web of Science ®Google Scholar
• Wang H, Wang L, Erdjument-Bromage H, et al. Role of histone H2A ubiquitination in Polycomb silencing. Nature 2004;431(7010):873-8
   PubMed Web of Science ®Google Scholar
• Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011;17(9):2613-18
   PubMed Web of Science ®Google Scholar
• McCabe MT, Graves AP, Ganji G, et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci USA 2012;109(8):2989-94
   PubMed Web of Science ®Google Scholar
• Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42(2):181-5
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011;43(9):830-7
   PubMed Web of Science ®Google Scholar
• Wigle TJ, Knutson SK, Jin L, et al. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett 2011;585(19):3011-14
   PubMed Web of Science ®Google Scholar
• Yap DB, Chu J, Berg T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011;117(8):2451-9
   PubMed Web of Science ®Google Scholar
• Arisan S, Buyuktuncer ED, Palavan-Unsal N, et al. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 2005;75(3):252-7
   PubMedGoogle Scholar
• Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003;100(20):11606-11
   PubMed Web of Science ®Google Scholar
• Matsukawa Y, Semba S, Kato H, et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 2006;97(6):484-91
   PubMedGoogle Scholar
• Raman JD, Mongan NP, Tickoo SK, et al. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 2005;11(24 Pt 1):8570-6
   PubMedGoogle Scholar
• Sudo T, Utsunomiya T, Mimori K, et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005;92(9):1754-8
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419(6907):624-9
   PubMed Web of Science ®Google Scholar
• Watanabe H, Soejima K, Yasuda H, et al. Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int 2008;8:15
   PubMed Web of Science ®Google Scholar
• Weikert S, Christoph F, Kollermann J, et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 2005;16(2):349-53
   PubMed Web of Science ®Google Scholar
• Orzan F, Pellegatta S, Poliani PL, et al. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol 2011;37(4):381-94
   PubMed Web of Science ®Google Scholar
• Zhang R, Wang R, Chang H, et al. Downregulation of Ezh2 expression by RNA interference induces cell cycle arrest in the G0/G1 phase and apoptosis in U87 human glioma cells. Oncol Rep 2012;28(6):2278-84
   PubMed Web of Science ®Google Scholar
• Smits M, Nilsson J, Mir SE, et al. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 2010;1(8):710-20
   PubMedGoogle Scholar
• Crea F, Hurt EM, Farrar WL. Clinical significance of Polycomb gene expression in brain tumors. Mol Cancer 2010;9:265
   PubMed Web of Science ®Google Scholar
• Ott M, Litzenburger UM, Sahm F, et al. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase. PLoS One 2012;7(10):e47663
   PubMed Web of Science ®Google Scholar
• Wu Z, Wang Q, Wang L, et al. Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients. J Neurol Sci 2013;335(1-2):191-6
   PubMed Web of Science ®Google Scholar
• Abdouh M, Facchino S, Chatoo W, et al. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 2009;29(28):8884-96
   PubMed Web of Science ®Google Scholar
• Chan KM, Fang D, Gan H, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 2013;27(9):985-90
   PubMed Web of Science ®Google Scholar
• Suva ML, Riggi N, Janiszewska M, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009;69(24):9211-18
   PubMed Web of Science ®Google Scholar
• Kim E, Kim M, Woo DH, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013;23(6):839-52
   PubMed Web of Science ®Google Scholar
• Weng YL, An R, Shin J, et al. DNA modifications and neurological disorders. Neurotherapeutics 2013;10(4):556-67
   PubMed Web of Science ®Google Scholar
• Rottach A, Leonhardt H, Spada F. DNA methylation-mediated epigenetic control. J Cell Biochem 2009;108(1):43-51
   PubMedGoogle Scholar
• Zhao YE, Wu LP. RAPD-SCAR marker and genetic relationship analysis of three Demodex species (Acari: demodicidae). Parasitol Res 2012;110(6):2395-402
   PubMedGoogle Scholar
• Brenner C, Fuks F. DNA methyltransferases: facts, clues, mysteries. Curr Top Microbiol Immunol 2006;301:45-66
   PubMed Web of Science ®Google Scholar
• Turek-Plewa J, Jagodzinski PP. The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol Biol Lett 2005;10(4):631-47
   PubMed Web of Science ®Google Scholar
• Roloff TC, Ropers HH, Nuber UA. Comparative study of methyl-CpG-binding domain proteins. BMC Genomics 2003;4(1):1
   PubMed Web of Science ®Google Scholar
• Kimura H, Shiota K. Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J Biol Chem 2003;278(7):4806-12
   PubMed Web of Science ®Google Scholar
• Cimmino L, Abdel-Wahab O, Levine RL, et al. TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell 2011;9(3):193-204
   PubMed Web of Science ®Google Scholar
• Frauer C, Rottach A, Meilinger D, et al. Different binding properties and function of CXXC zinc finger domains in Dnmt1 and Tet1. PLoS One 2011;6(2):e16627
   Google Scholar
• Iyer L M, Tahiliani M, Rao A, et al. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 2009;8(11):1698-710
   PubMedGoogle Scholar
• Williams K, Christensen J, Pedersen MT, et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011;473(7347):343-8
   PubMed Web of Science ®Google Scholar
• Wu H, D’Alessio AC, Ito S, et al. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 2011;473(7347):389-93
   PubMed Web of Science ®Google Scholar
• Freudenberg JM, Ghosh S, Lackford BL, et al. Acute depletion of Tet1-dependent 5-hydroxymethylcytosine levels impairs LIF/Stat3 signaling and results in loss of embryonic stem cell identity. Nucleic Acids Res 2012;40(8):3364-77
   PubMed Web of Science ®Google Scholar
• Rauch T, Wang Z, Zhang X, et al. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci USA 2007;104(13):5527-32
   PubMed Web of Science ®Google Scholar
• Vire E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439(7078):871-4
   PubMed Web of Science ®Google Scholar
• Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007;39(2):157-8
   PubMed Web of Science ®Google Scholar
• Kreth S, Thon N, Eigenbrod S, et al. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One 2011;6(2):e17156
   Web of Science ®Google Scholar
• Mann J, Chu DC, Maxwell A, et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010;138(2):705-14; 714 e1-4
   PubMed Web of Science ®Google Scholar
• Pancione M, Sabatino L, Fucci A, et al. Epigenetic silencing of peroxisome proliferator-activated receptor gamma is a biomarker for colorectal cancer progression and adverse patients’ outcome. PLoS One 2010;5(12):e14229
   Google Scholar
• Cartron PF, Nadaradjane A, Lepape F, et al. Identification of TET1 partners that control Its DNA-demethylating function. Genes Cancer 2013;4(5-6):235-41
   PubMedGoogle Scholar
• Filipowicz W, Jaskiewicz L, Kolb FA, et al. Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol 2005;15(3):331-41
   PubMed Web of Science ®Google Scholar
• He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5(7):522-31
   PubMed Web of Science ®Google Scholar
• Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011;39(Database issue):D152-7
   PubMed Web of Science ®Google Scholar
• Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010;11(9):597-610
   PubMed Web of Science ®Google Scholar
• Sontheimer EJ, Carthew RW. Silence from within: endogenous siRNAs and miRNAs. Cell 2005;122(1):9-12
   PubMedGoogle Scholar
• Hong L, Yang Z, Ma J, et al. Function of miRNA in controlling drug resistance of human cancers. Curr Drug Targets 2013;14(10):1118-27
   PubMed Web of Science ®Google Scholar
• Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol 2013;15(6):546-54
   PubMed Web of Science ®Google Scholar
• Yates LA, Norbury CJ, Gilbert RJ. The long and short of microRNA. Cell 2013;153(3):516-19
   PubMed Web of Science ®Google Scholar
• Xiaoping L, Zhibin Y, Wenjuan L, et al. CPEB1, a histone-modified hypomethylated gene, is regulated by miR-101 and involved in cell senescence in glioma. Cell Death Dis 2013;4:e675
   PubMed Web of Science ®Google Scholar
• Guo P, Lan J, Ge J, et al. miR-708 acts as a tumor suppressor in human glioblastoma cells. Oncol Rep 2013;30(2):870-6
   PubMed Web of Science ®Google Scholar
• Rao ZY, Cai MY, Yang GF, et al. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 2010;31(9):1576-83
   PubMedGoogle Scholar
• Ren G, Baritaki S, Marathe H, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res 2012;72(12):3091-104
   PubMed Web of Science ®Google Scholar
• Qiu S, Huang D, Yin D, et al. Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. Biochim Biophys Acta 2013;1832(10):1697-707
   PubMed Web of Science ®Google Scholar
• Lee ST, Chu K, Oh H J, et al. Let-7 microRNA inhibits the proliferation of human glioblastoma cells. J Neurooncol 2011;102(1):19-24
   PubMedGoogle Scholar
• Kong D, Heath E, Chen W, et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One 2012;7(3):e33729
   Google Scholar
• Chen Z, Cheng Q, Ma Z, et al. Overexpression of RKIP inhibits cell invasion in glioma cell lines through upregulation of miR-98. Biomed Res Int 2013;2013:695179
   PubMedGoogle Scholar
• Huang SD, Yuan Y, Zhuang CW, et al. MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma. Mol Cancer 2012;11:51
   PubMed Web of Science ®Google Scholar
• An L, Liu Y, Wu A, et al. microRNA-124 inhibits migration and invasion by down-regulating ROCK1 in glioma. PLoS One 2013;8(7):e69478
   Google Scholar
• Lv Z, Yang L. MiR-124 inhibits the growth of glioblastoma through the downregulation of SOS1. Mol Med Rep 2013;8(2):345-9
   PubMed Web of Science ®Google Scholar
• Zheng F, Liao YJ, Cai MY, et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012;61(2):278-89
   PubMed Web of Science ®Google Scholar
• Li KK, Yang L, Pang JC, et al. MIR-137 suppresses growth and invasion, is downregulated in oligodendroglial tumors and targets CSE1L. Brain Pathol 2013;23(4):426-39
   PubMedGoogle Scholar
• Luo C, Tetteh PW, Merz PR, et al. miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J Invest Dermatol 2013;133(3):768-75
   PubMed Web of Science ®Google Scholar
• Willemsen MH, Valles A, Kirkels LA, et al. Chromosome 1p21.3 microdeletions comprising DPYD and MIR137 are associated with intellectual disability. J Med Genet 2011;48(12):810-18
   PubMed Web of Science ®Google Scholar
• Qian X, Zhao P, Li W, et al. MicroRNA-26a promotes tumor growth and angiogenesis in glioma by directly targeting prohibitin. CNS Neurosci Ther 2013;19(10):804-12
   PubMed Web of Science ®Google Scholar
• Lu J, He ML, Wang L, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011;71(1):225-33
   PubMed Web of Science ®Google Scholar